2024 : 7 : 17
Monireh Mahmoodi

Monireh Mahmoodi

Academic rank: Assistant Professor
ORCID: https://orcid.org/0000-0001-8383-6150
Education: PhD.
ScopusId: 35102803500
Faculty: Science
Address: Arak University


Harnessing Normal and Engineered Mesenchymal Stem Cells Derived Exosomes for Cancer Therapy: Opportunity and Challenges
MSCs; mesenchymal stem cells; exosomes; tumor; drug delivery
Journal International Journal of Molecular Sciences
Researchers Mehdi Ahmadi ، Monireh Mahmoodi ، Maryam Shoaran ، Fereshteh Nazari-Khanamiri ، Jafar Rezaie


There remains a vital necessity for new therapeutic approaches to combat metastatic cancers, which cause globally over 8 million deaths per year. Mesenchymal stem cells (MSCs) display aptitude as new therapeutic choices for cancer treatment. Exosomes, the most important mediator of MSCs, regulate tumor progression. The potential of harnessing exosomes from MSCs (MSCs-Exo) in cancer therapy is now being documented. MSCs-Exo can promote tumor progression by affecting tumor growth, metastasis, immunity, angiogenesis, and drug resistance. However, contradictory evidence has suggested that MSCs-Exo suppress tumors through several mechanisms. Therefore, the exact association between MSCs-Exo and tumors remains controversial. Accordingly, the applications of MSCs-Exo as novel drug delivery systems and standalone therapeutics are being extensively explored. In addition, engineering MSCs-Exo for targeting tumor cells has opened a new avenue for improving the efficiency of antitumor therapy. However, effective implementation in the clinical trials will need the establishment of standards for MSCs-Exo isolation and characterization as well as loading and engineering methods. The studies outlined in this review highlight the pivotal roles of MSCs-Exo in tumor progression and the promising potential of MSCs-Exo as therapeutic drug delivery vehicles for cancer treatment.